RecruitingPhase 1NCT07406334

A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose

A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 To 15 Months of Age Receiving a Single Booster Dose

Sponsor

GlaxoSmithKline

Enrollment

45 participants

Start Date

May 15, 2026

Study Type

INTERVENTIONAL

Conditions

Pneumonia, Bacterial

Summary

The main purpose of this study is to assess the safety and reactogenicity of a single dose of the new pneumococcal vaccine (called Pn-MAPS30plus) in toddlers who have previously completed a two-dose primary vaccination series with PCV used in local immunization program. PCV20 will be used as a comparator for this study.

Eligibility

Min Age: 12 MonthsMax Age: 15 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying PCV20 and a biological treatment called Pn-MAPS30plus for people with pneumonia, bacterial. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 12 Months to 15 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.